Press releases
- Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
- Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
- Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
- Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
- Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
- Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
- Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
- Moleculin Reports Full Year 2023 Financial Results
- Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
More ▼
Key statistics
As of last trade Moleculin Biotech Inc (MOL:FRA) traded at 0.43, -89.22% above its 52-week low of 3.99, set on Sep 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 0.43 |
Average volume | -- |
---|---|
Shares outstanding | 2.23m |
Free float | 2.12m |
P/E (TTM) | -- |
Market cap | 11.27m USD |
EPS (TTM) | -15.06 USD |
Data delayed at least 15 minutes, as of Mar 21 2024.
More ▼